Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma
|ClinicalTrials.gov Identifier: NCT00139360|
Recruitment Status : Completed
First Posted : August 31, 2005
Last Update Posted : August 27, 2015
Haukeland University Hospital
Norwegian Cancer Society
Information provided by (Responsible Party):
Oddbjørn Straume, MD PhD, Haukeland University Hospital
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Completed|
|Primary Completion Date :||July 2011|
|Study Completion Date :||July 2011|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Schuster C, Akslen LA, Straume O. Expression of Heat Shock Protein 27 in Melanoma Metastases Is Associated with Overall Response to Bevacizumab Monotherapy: Analyses of Predictive Markers in a Clinical Phase II Study. PLoS One. 2016 May 11;11(5):e0155242. doi: 10.1371/journal.pone.0155242. eCollection 2016.
Schuster C, Eikesdal HP, Puntervoll H, Geisler J, Geisler S, Heinrich D, Molven A, Lønning PE, Akslen LA, Straume O. Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. PLoS One. 2012;7(6):e38364. doi: 10.1371/journal.pone.0038364. Epub 2012 Jun 15.